Lamotrigine in the treatment of bipolar depression

C. L. Bowden, P. Mitchell, T. Suppes

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Several case reports and open studies have reported the efficacy of lamotrigine in bipolar depression. A randomised placebo-controlled 7-week study comparing two doses of lamotrigine with placebo in 195 patients with moderate to severe bipolar depression has now been completed. Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS). A response, defined as more than 50% improvement on the MADRS occurred in 56 and 48% of the lamotrigine 200 and 50 mg/day groups, respectively, compared with 29% for placebo (P<0.05). There was no evidence that lamotrigine destabilised mood or precipitated mania. Tolerability was good and there were no cases of serious rashes. Preliminary results from an ongoing study also indicate that lamotrigine is more effective than gabapentin in bipolar depression. In conclusion, lamotrigine is effective in alleviating bipolar depression, without causing mood destabilisation. Slow dosage escalation yields good tolerability. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish (US)
JournalEuropean Neuropsychopharmacology
Volume9
Issue numberSUPPL. 4
DOIs
StatePublished - Aug 1999

Fingerprint

Bipolar Disorder
Placebos
Therapeutics
Depression
lamotrigine
Exanthema

Keywords

  • Bipolar depression
  • Efficacy
  • Lamotrigine
  • Placebo-controlled trial
  • Tolerability

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

Lamotrigine in the treatment of bipolar depression. / Bowden, C. L.; Mitchell, P.; Suppes, T.

In: European Neuropsychopharmacology, Vol. 9, No. SUPPL. 4, 08.1999.

Research output: Contribution to journalArticle

Bowden, C. L. ; Mitchell, P. ; Suppes, T. / Lamotrigine in the treatment of bipolar depression. In: European Neuropsychopharmacology. 1999 ; Vol. 9, No. SUPPL. 4.
@article{22b025fcd8ef473daf77fcaade5281de,
title = "Lamotrigine in the treatment of bipolar depression",
abstract = "Several case reports and open studies have reported the efficacy of lamotrigine in bipolar depression. A randomised placebo-controlled 7-week study comparing two doses of lamotrigine with placebo in 195 patients with moderate to severe bipolar depression has now been completed. Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS). A response, defined as more than 50{\%} improvement on the MADRS occurred in 56 and 48{\%} of the lamotrigine 200 and 50 mg/day groups, respectively, compared with 29{\%} for placebo (P<0.05). There was no evidence that lamotrigine destabilised mood or precipitated mania. Tolerability was good and there were no cases of serious rashes. Preliminary results from an ongoing study also indicate that lamotrigine is more effective than gabapentin in bipolar depression. In conclusion, lamotrigine is effective in alleviating bipolar depression, without causing mood destabilisation. Slow dosage escalation yields good tolerability. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "Bipolar depression, Efficacy, Lamotrigine, Placebo-controlled trial, Tolerability",
author = "Bowden, {C. L.} and P. Mitchell and T. Suppes",
year = "1999",
month = "8",
doi = "10.1016/S0924-977X(99)00024-3",
language = "English (US)",
volume = "9",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Lamotrigine in the treatment of bipolar depression

AU - Bowden, C. L.

AU - Mitchell, P.

AU - Suppes, T.

PY - 1999/8

Y1 - 1999/8

N2 - Several case reports and open studies have reported the efficacy of lamotrigine in bipolar depression. A randomised placebo-controlled 7-week study comparing two doses of lamotrigine with placebo in 195 patients with moderate to severe bipolar depression has now been completed. Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS). A response, defined as more than 50% improvement on the MADRS occurred in 56 and 48% of the lamotrigine 200 and 50 mg/day groups, respectively, compared with 29% for placebo (P<0.05). There was no evidence that lamotrigine destabilised mood or precipitated mania. Tolerability was good and there were no cases of serious rashes. Preliminary results from an ongoing study also indicate that lamotrigine is more effective than gabapentin in bipolar depression. In conclusion, lamotrigine is effective in alleviating bipolar depression, without causing mood destabilisation. Slow dosage escalation yields good tolerability. Copyright (C) 1999 Elsevier Science B.V.

AB - Several case reports and open studies have reported the efficacy of lamotrigine in bipolar depression. A randomised placebo-controlled 7-week study comparing two doses of lamotrigine with placebo in 195 patients with moderate to severe bipolar depression has now been completed. Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS). A response, defined as more than 50% improvement on the MADRS occurred in 56 and 48% of the lamotrigine 200 and 50 mg/day groups, respectively, compared with 29% for placebo (P<0.05). There was no evidence that lamotrigine destabilised mood or precipitated mania. Tolerability was good and there were no cases of serious rashes. Preliminary results from an ongoing study also indicate that lamotrigine is more effective than gabapentin in bipolar depression. In conclusion, lamotrigine is effective in alleviating bipolar depression, without causing mood destabilisation. Slow dosage escalation yields good tolerability. Copyright (C) 1999 Elsevier Science B.V.

KW - Bipolar depression

KW - Efficacy

KW - Lamotrigine

KW - Placebo-controlled trial

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=0032781865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032781865&partnerID=8YFLogxK

U2 - 10.1016/S0924-977X(99)00024-3

DO - 10.1016/S0924-977X(99)00024-3

M3 - Article

VL - 9

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - SUPPL. 4

ER -